Filing Flows › RenovoRx (RNXT) › Q3 2026 › vs Q2 2026
RenovoRx (RNXT) Q3 2026 vs Q2 2026 (quarter over quarter)
RenovoRx's revenue rose $157K (+17%) from $909K in Q2 2026 to $1.1M in Q3 2026.
RenovoRx, Q3 2026: revenue $1.1M (+301% year over year), operating margin -303.6%, net loss $3.6M, operating cash flow −$2.5M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.1M | $909K | $157K | +17% |
| Net loss | $3.6M | $2.9M | $736K | +25% |
| Costs & expenses | $4.7M | $4.3M | $455K | +11% |
| Operating costs | $4.3M | $4.3M | $44K | +1% |
| Interest & other, net | $411K | −$438K | $849K | — |
| Cost of revenue | $188K | $143K | $45K | +31% |
| Research & development | $1.2M | $1.2M | $41K | +3% |
| SG&A | $2.9M | $2.9M | −$42K | -1% |
| Operating cash sources | $3.6M | $2.9M | $736K | +25% |
| Depreciation | $5K | $5K | $0 | 0% |
| Share-based compensation | $469K | $570K | −$101K | -18% |
| Working capital & other | $634K | −$531K | $1.2M | — |
| Cash used in operations | $2.5M | $2.9M | −$328K | -11% |
| Net loss absorbed | $3.6M | $2.9M | $736K | +25% |
Questions
How much did RenovoRx's revenue grow quarter over quarter in Q3 2026?
RenovoRx's revenue rose $157K (+17%) from $909K in Q2 2026 to $1.1M in Q3 2026.